Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Table 1 Demographic and baseline clinical characteristics of patients with neuroendocrine tumors, n = 36

Characteristics	Number of patients
Sex
Male	20 (55.6%)
Female	16 (44.4%)
Comorbidities
Hypertension	15 (41.7%)
DM	7 (19.4%)
Smoking habits	9 (25.0%)
Cancer history	5 (13.9%)
Symptoms prior to diagnosis
Abdominal pain	12 (33.3%)
Gastrointestinal and carcinoid symptoms	6 (16.7%)
Weight loss	5 (12.5%)
Asymptomatic	4 (11.1%)
Primary tumor site
Gastrointestinal tract	19 (52.8%)
Pancreas	10 (27.8%)
Nongastropancreatic NET	4 (11.1%)
Endobronchial NETs	2
Thymic	1
Histologic grade
Grade 1	15 (41.7%)
Grade 2	18 (50.0%)
Grade 3 (2 NEC + 1 TNE)	3 (8.3%)
Site of metastasis
Liver	33 (91.7%)
Lymph nodes	18 (50.0%)
Bone	10 (27.8%)
Peritoneum	9 (25.0%)
Lungs	4 (11.1%)
Primary tumor resection	20 (55.6%)
Metastasis resection	7 (19.4%)
Primary treatment before PRRT
SSA	36 (100%)
Everolimus	24 (66.7%)
Sunitinib	10 (27.8%)
Interferon	10 (27.8%)
Chemotherapy	6 (16.7%)
Liver directed therapy
Chemoembolization	3
Radioembolization	1

NEC: Neuroendocrine carcinoma; NET: Neuroendocrine tumors; PRRT: Peptide receptor radionuclide therapy; SSA: Somatostatin analogues.